中国肺癌杂志2017，Vol.20Issue(2)：114-123,10.DOI:10.3779/j.issn.1009-3419.2017.02.06
非小细胞肺癌脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂治疗的临床研究
Clinical Experience with First-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with Brain Metastasis
摘要
Abstract
Background and objective A survival analysis and the influencing factors for non-small cell lung cancer (NSCLC) patients with brain metastases accepting first-generation epidermal growth factor receptor tyrosine kinase inhibi-tor (EGFR-TKIs) treatment have not yet been elucidated to date. In this study, we collected and analyzed the survival data of NSCLC patients with brain metastasis to obtain evidence and to provide guidance in clinical practice.Methods NSCLC patients with brain metastases who were treated with first-generation EGFR-TKIs were retrospectively collected in 2012-2013 from Shanghai Chest Hospital, Shanghai Jiao Tong University. The Kaplan-Meier method and Cox regression were performed for univariate and multivariate analyses, respectively, to explore the independent predictors influencing the survival of patients with NSCLC brain metastases.Results The median progression-free survival (PFS) and median overall survival (OS) of all patients treated with first-generation EGFR-TKIs were 10.0 months (95%CI: 8.3-11.7) and 28.0 months (95%CI: 22.9-33.1), respectively. Pathological subtypes were the independent predictors of PFS (P=0.001), and tumor differentiations were the independent predictors of OS (P=0.050).Conclusion First-generation EGFR-TKIs showed promising efficacy in NSCLC patients with brain metastases. PFS was longer in patients with adenocarcinoma than in those with a non-adenocarcinoma sub-type. OS was longer in patients with differentiated tumors than in those who developed poorly differentiated tumors.关键词
肺肿瘤/脑转移/表皮生长因子受体-酪氨酸激酶抑制剂/生存期Key words
Lung neoplasms/Brain metastases/Epidermal growth factor receptor-tyrosine kinase inhibitors/Survival引用本文复制引用
董惠幸,崔少华,潘峰,董莉莉,牛艳洁,赵怡卓,顾爱琴,金晓燕,姜丽岩..非小细胞肺癌脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂治疗的临床研究[J].中国肺癌杂志,2017,20(2):114-123,10.基金项目
本研究受国家自然科学基金面上项目(No.81472175)和上海市卫生和计划生育委员会重点项目(No.20134007)资助This study was supported by the National Nature Science Foundation of China (No.81472175) and Shanghai Municipal Commission of Health and Family Planning Key Projects (Both to Liyan JIANG)(No.20134007). （No.81472175）
